Patents by Inventor Denise M. Kenski

Denise M. Kenski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
    Patent number: 11932854
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.
    Type: Grant
    Filed: October 25, 2021
    Date of Patent: March 19, 2024
    Assignee: Sirna Therapeutics, Inc.
    Inventors: Mark Cancilla, James John Cunningham, William Michael Flanagan, Henry J. Haringsma, Denise M. Kenski, Matthew G. Stanton, Steven M. Stirdivant, Aarron T. Willingham
  • SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
    Publication number: 20230348904
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.
    Type: Application
    Filed: November 10, 2022
    Publication date: November 2, 2023
    Inventors: Brian Allen Carr, Vasant R. Jadhav, Denise M. Kenski, David M. Tellers, Aarron T. Willingham
  • Short interfering nucleic acid (siNA) compositions
    Patent number: 11530407
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.
    Type: Grant
    Filed: February 18, 2020
    Date of Patent: December 20, 2022
    Assignee: Sirna Therapeutics, Inc.
    Inventors: Brian Allen Carr, Vasant R. Jadhav, Denise M. Kenski, David M. Tellers, Aarron T. Willingham
  • RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (SINA)
    Publication number: 20220195433
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (MAO against target gene expression.
    Type: Application
    Filed: October 25, 2021
    Publication date: June 23, 2022
    Inventors: Mark Cancilla, James John Cunningham, William Michael Flanagan, Henry J. Haringsma, Denise M. Kenski, Matthew G. Stanton, Steven M. Stirdivant, Aarron T. Willingham
  • RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
    Patent number: 11193126
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: December 7, 2021
    Assignee: SIRNA THERAPEUTICS, INC.
    Inventors: Mark Cancilla, James John Cunningham, William Michael Flanagan, Henry J. Haringsma, Denise M. Kenski, Matthew G. Stanton, Steven M. Stirdivant, Aarron T. Willingham
  • SHORT INTERFERING NUCLEIC ACID (SINA) COMPOSITIONS
    Publication number: 20200392499
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.
    Type: Application
    Filed: February 18, 2020
    Publication date: December 17, 2020
    Inventors: Brian Allen Carr, Vasant R. Jadhav, Denise M. Kenski, David M. Tellers, Aarron T. Willingham
  • Short interfering nucleic acid (siNA) compositions
    Patent number: 10689648
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: June 23, 2020
    Assignee: SIRNA THERAPEUTICS, INC.
    Inventors: Brian Allen Carr, Vasant R. Jadhav, Denise M. Kenski, David M. Tellers, Aarron T. Willingham
  • RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
    Publication number: 20180362977
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.
    Type: Application
    Filed: April 6, 2018
    Publication date: December 20, 2018
    Inventors: Mark Cancilla, James John Cunningham, William Michael Flanagan, Henry J. Haringsma, Denise M. Kenski, Matthew G. Stanton, Steven M. Stirdivant, Aarron T. Willingham
  • RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
    Patent number: 9970005
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: May 15, 2018
    Assignee: SIRNA THERAPEUTICS, INC.
    Inventors: Mark Cancilla, James John Cunningham, William Michael Flanagan, Henry J. Haringsma, Denise M. Kenski, Matthew G. Stanton, Steven M. Stirdivant, Aarron T. Willingham
  • SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
    Publication number: 20180105812
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.
    Type: Application
    Filed: August 23, 2017
    Publication date: April 19, 2018
    Inventors: Brian Allen Carr, Vasant R. Jadhav, Denise M. Kenski, David M. Tellers, Aarron T. Willingham
  • Genetic variations associated with tumors
    Patent number: 9631240
    Abstract: Nucleotide and amino acid variations associated with tumors are provided. Methods for detecting variations and for diagnosing and treating tumors are provided.
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: April 25, 2017
    Assignee: Genentech, Inc.
    Inventors: Zhengyan Kan, Denise M. Kenski, Brock Peters, Somasekar Seshagiri
  • Method for rapidly evaluating performance of short interfering RNA with novel chemical modifications
    Patent number: 9512426
    Abstract: It is an object of the instant invention to provide a method for the rapid evaluation of novel sugar modifications to be used in siRNA synthesis including the rapid evaluation of chemical modification patterns within the siRNA to effectuate increased stability and ultimately increased efficacy of a siRNA therapeutic. It is a further object of the instant invention to provide novel nucleosides useful for siRNA therapy.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: December 6, 2016
    Assignee: SIRNA THERAPEUTICS, INC.
    Inventors: Gabor Butora, Ian W. Davies, William Michael Flanagan, Wenlang Fu, Denise M. Kenski, Ning Qi
  • RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
    Publication number: 20160264964
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.
    Type: Application
    Filed: December 30, 2015
    Publication date: September 15, 2016
    Applicant: SIRNA THERAPEUTICS, INC.
    Inventors: Mark Cancilla, James John Cunningham, Michael William Flanagan, Henry J. Haringsma, Denise M. Kenski, Matthew G. Stanton, Steven M. Stirdivant, Aarron T. Willingham
  • SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
    Publication number: 20150299696
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.
    Type: Application
    Filed: April 26, 2013
    Publication date: October 22, 2015
    Applicant: Sirna Therapeutics, Inc.
    Inventors: Brian Allen Carr, Vasant R. Jadhav, Denise M. Kenski, David M. Tellers, Aarron T. Willingham
  • METHOD FOR RAPIDLY EVALUATING PERFORMANCE OF SHORT INTERFERING RNA WITH NOVEL CHEMICAL MODIFICATIONS
    Publication number: 20150132761
    Abstract: It is an object of the instant invention to provide a method for the rapid evaluation of novel sugar modifications to be used in siRNA synthesis including the rapid evaluation of chemical modification patterns within the siRNA to effectuate increased stability and ultimately increased efficacy of a siRNA therapeutic. It is a further object of the instant invention to provide novel nucleosides useful for siRNA therapy.
    Type: Application
    Filed: October 3, 2014
    Publication date: May 14, 2015
    Inventors: Gabor Butora, Ian W. Davies, William Michael Flanagan, Wenlang Fu, Denise M. Kenski, Ning Qi
  • GENETIC VARIATIONS ASSOCIATED WITH TUMORS
    Publication number: 20150010537
    Abstract: Nucleotide and amino acid variations associated with tumors are provided. Methods for detecting variations and for diagnosing and treating tumors are provided.
    Type: Application
    Filed: March 6, 2014
    Publication date: January 8, 2015
    Applicant: Genentech, Inc.
    Inventors: Zhengyan Kan, Denise M. Kenski, Brock Peters, Somasekar Seshagiri
  • Method for rapidly evaluating performance of short interfering RNA with novel chemical modifications
    Patent number: 8877439
    Abstract: It is an object of the instant invention to provide a method for the rapid evaluation of novel sugar modifications to be used in siRNA synthesis including the rapid evaluation of chemical modification patterns within the siRNA to effectuate increased stability and ultimately increased efficacy of a siRNA therapeutic. It is a further object of the instant invention to provide novel nucleosides useful for siRNA therapy.
    Type: Grant
    Filed: December 9, 2010
    Date of Patent: November 4, 2014
    Assignee: Sirna Therapeutics, Inc.
    Inventors: Gabor Butora, Ian W. Davies, William Michael Flanagan, Wenlang Fu, Denise M. Kenski, Ning Qi
  • Genetic variations associated with tumors
    Patent number: 8680041
    Abstract: Nucleotide and amino acid variations associated with tumors are provided. Methods for detecting variations and for diagnosing and treating tumors are provided.
    Type: Grant
    Filed: October 24, 2007
    Date of Patent: March 25, 2014
    Assignee: Genentech, Inc.
    Inventors: Zhengyan Kan, Denise M. Kenski, Brock Peters, Somasekar Seshagiri
  • RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
    Publication number: 20130217756
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.
    Type: Application
    Filed: October 25, 2011
    Publication date: August 22, 2013
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Mark Cancilla, James John Cunningham, Michael W. Flanagan, Henry J. Haringsma, Denise M. Kenski, Matthew G. Stanton, Steven M. Stirdivant, Aarron T. Willingham
  • Method For Rapidly Evaluating Performance Of Short Interfering RNA With Novel Chemical Modifications
    Publication number: 20120252027
    Abstract: It is an object of the instant invention to provide a method for the rapid evaluation of novel sugar modifications to be used in siRNA synthesis including the rapid evaluation of chemical modification patterns within the siRNA to effectuate increased stability and ultimately increased efficacy of a siRNA therapeutic. It is a further object of the instant invention to provide novel nucleosides useful for siRNA therapy.
    Type: Application
    Filed: December 9, 2010
    Publication date: October 4, 2012
    Inventors: Gabor Butora, Ian W. Davies, William Michael Flanagan, Wenlang Fu, Denise M. Kenski, Ning Qi